Angiotensin converting enzyme and Alzheimer's disease


1. Institute of Biomedical Chemistry, Russian Academy of Medical Sciences (RAMS)
Type: Review
DOI: 10.18097/pbmc20135901005      UDK: 577.152.341*51      PubMed Id: 23650720
Year: 2013 vol: 59  issue:1  pages: 5-24
Abstract: Alzheimer's disease (AD) is an incurable degenerative disease of the central nervous system, leading to dementia. The basis of AD is neurodegenerative process that leads to death of neurons in the cerebral cortex. This neurodegenerative process is associated with the formation of neurofibrillary tangles in the brain and the deposition of senile plaques, the main component of which is a beta-amyloid peptide (Ab). Risk factors for AD are age, as well as hypertension, atherosclerosis, diabetes and hypercholesterolemia in the pathogenesis of which involved angiotensin converting enzyme (ACE) – key enzyme of the renin-angiotensin (RAS) and kallikrein-kinin (KKS) systems. Recently it was discovered that ACE, along with other metallopeptidases, participates in the metabolism of Ab, cleaving the bonds at the N-terminal and C-terminal region of the molecule Ab. The role of the ACE in the degradation processes of Ab takes an interest. It is associated with the fact that the using of ACE inhibitors is the main therapeutic approach used in the treatment of various forms of hypertension and other cardiovascular diseases. However, until now not been resolved, can be used antihypertensive drugs that inhibit RAS for the treatment or prevention of AD. Currently, there are numerous studies on finding the relationship between RAS and AD.
Download PDF:
Reference: Kugaevskaya E.V., Angiotensin converting enzyme and Alzheimer's disease, Biomeditsinskaya khimiya, 2013, vol: 59(1), 5-24.
This paper is also available as the English translation:10.1134/S199075081201009X
 In press